ScholarIQanswers from OpenAlex & ORCID
Junji Furuse
ResearcherPublications, citations & collaboration network
Junji Furuse is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Junji Furuse have?
ScholarIQindexed works
Junji Furuse has 724 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Junji Furuse have?
ScholarIQcitation count
Junji Furuse has 28,783 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Junji Furuse?
ScholarIQh-index
Junji Furuse has an h-index of 75 in OpenAlex.
What is the i10-index of Junji Furuse?
ScholarIQi10-index
Junji Furuse has an i10-index of 300 in OpenAlex.
What is the ORCID of Junji Furuse?
ScholarIQorcid
The ORCID for Junji Furuse is on the source record.
What is the OpenAlex record for Junji Furuse?
ScholarIQopenalex
The OpenAlex for Junji Furuse is on the source record.
What are the most-cited papers on Junji Furuse?
ScholarIQmost cited works
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz‐Josef Klümpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel, Arndt Vogel, Mehmet Akce, Inmaculada Alés Díaz, Gustavo R. Alves, Sumitra Anand, Çağatay Arslan, Jamil Asselah, Eric Assenat, F. Aubin, Li‐Yuan Bai, Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Jen‐Shi Chen, Jen‐Shi Chen, Ming-Huang Chen, Ashley Cheng, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, T Shimamura, Masayuki Sho, Masayuki Kitano, Ann‐Lii Cheng, Kazuhiro Mizumoto, Jen‐Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Satō, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Yoshiaki Nakamura, Hiroya Taniguchi, Masafumi Ikeda, Hideaki Bando, Ken Kato, Chigusa Morizane, Taito Esaki, Yoshito Komatsu, Yasuyuki Kawamoto, Naoki Takahashi, Makoto Ueno, Yoshinori Kagawa, Tomohiro Nishina, Takeshi Kato, Yoshiyuki Yamamoto, Junji Furuse, Tadamichi Denda, Hisato Kawakami, Eiji Oki, Takako Eguchi Nakajima, Naohiro Nishida, Kensei Yamaguchi, Hisateru Yasui, Masahiro Goto, Nobuhisa Matsuhashi, Koushiro Ohtsubo, Kentaro Yamazaki, Akihito Tsuji, Wataru Okamoto, Katsuya Tsuchihara, Takeharu Yamanaka, Miki Izumi, Yasutoshi Sakamoto, Hiroko Ichiki, Masayuki Hata, Riu Yamashita, Atsushi Ohtsu, Justin I. Odegaard, Takayuki Yoshino
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Hiroshi Katayama, Makoto Ueno, Masafumi Ikeda, Masato Ozaka, Naohiro Okano, Kazuya Sugimori, Akira Fukutomi, Hiroki Hara, Nobumasa Mizuno, Hiroaki Yanagimoto, Keita Wada, Kazutoshi Tobimatsu, Kei Yane, Shoji Nakamori, Hiroyuki Yamaguchi, Akinori Asagi, Seigo Yukisawa, Yasushi Kojima, Ken Kawabe, Yasuyuki Kawamoto, Rie Sugimoto, Tomohisa Iwai, Kazuyoshi Nakamura, Hiroyoshi Miyakawa, Tatsuya Yamashita, A. Hosokawa, Tatsuya Ioka, Naoya Kato, Kazuhiko Shioji, Kyoko Shimizu, Toshio Nakagohri, Ken Kamata, Hiroshi Ishii, Junji Furuse
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Makoto Ueno, Masafumi Ikeda, Chigusa Morizane, Satoshi Kobayashi, Izumi Ohno, Shunsuke Kondo, Naohiro Okano, Keisuke Kimura, Suguru Asada, Yoshinobu Namba, Takuji Okusaka, Junji Furuse